Scripscan:Parenteral Drugs (India) Ltd
cmp:68
Code:524689
Story:Parenteral Drugs (India) Limited, together with its subsidiaries, operates as a healthcare company in India. The company engages in the research, production, and manufacturing of pharmaceutical products, such as intravenous infusion, tablets, capsules, liquids syrups, and injections. Its products include antibiotics and antibacterials, multivitamin and multiminerals, expectorant, analgesic and antipyretic infusion, oncology, and antioxidants.Parenteral Drugs India (PDIL) couple of years ago has set up a critical care division to market its product basket, including the Paracetamol-based IV fluid. PDIL targets peak revenues of Rs 150 crore from this in the next few years led by higher volumes and margins, high-end IV fluids like fat emulsions, aminoacids etc and anesthesia under as fundamentals may Piramal Healthcare. Besides, it has also strategically diversified into oncology, UNOPS (United Nations Offices for Project Services) supply, etc. PDIL aims to treble its revenues from its oncology business in the coming years led by robust sales in international markets.The company is also expanding its geographical reach beyond the domestic borders through its international JVs in Mauritius, Kenya, Kazakhstan etc. The stock has corrected a lot and looks to be a good hold at present levels.Its a buy at around 50-55 levels though.
cmp:68
Code:524689
Story:Parenteral Drugs (India) Limited, together with its subsidiaries, operates as a healthcare company in India. The company engages in the research, production, and manufacturing of pharmaceutical products, such as intravenous infusion, tablets, capsules, liquids syrups, and injections. Its products include antibiotics and antibacterials, multivitamin and multiminerals, expectorant, analgesic and antipyretic infusion, oncology, and antioxidants.Parenteral Drugs India (PDIL) couple of years ago has set up a critical care division to market its product basket, including the Paracetamol-based IV fluid. PDIL targets peak revenues of Rs 150 crore from this in the next few years led by higher volumes and margins, high-end IV fluids like fat emulsions, aminoacids etc and anesthesia under as fundamentals may Piramal Healthcare. Besides, it has also strategically diversified into oncology, UNOPS (United Nations Offices for Project Services) supply, etc. PDIL aims to treble its revenues from its oncology business in the coming years led by robust sales in international markets.The company is also expanding its geographical reach beyond the domestic borders through its international JVs in Mauritius, Kenya, Kazakhstan etc. The stock has corrected a lot and looks to be a good hold at present levels.Its a buy at around 50-55 levels though.
Posts
